Polycythemia vera epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (28 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Polycythemia vera}} | {{Polycythemia vera}} | ||
{{CMG}} {{AE}}{{MJK}} | {{CMG}} {{AE}} {{IO}} {{MJK}} {{shyam}} | ||
==Overview== | ==Overview== | ||
The incidence of polycythemia vera is approximately | The incidence of polycythemia vera is approximately 1.9 per 100,000 individuals per year in the US. The [[prevalence]] of polycythemia vera is 48 to 57 cases per 100,000 individuals in the United States. Males are more commonly affected than females. | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | ===Incidence=== | ||
The incidence of polycythemia vera is | *The [[incidence]] of polycythemia vera is about 1.9 per 100,000 individuals per year in the US. The incidence rate for men is 2.8 per 100,000 person-years, and is 1.3 per 100,000 person years for women.<ref name="pmid8092146">{{cite journal| author=Anía BJ, Suman VJ, Sobell JL, Codd MB, Silverstein MN, Melton LJ| title=Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989. | journal=Am J Hematol | year= 1994 | volume= 47 | issue= 2 | pages= 89-93 | pmid=8092146 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8092146 }} </ref> | ||
===Prevalence=== | ===Prevalence=== | ||
The prevalence of PV is estimated to be 44 to 57 cases per 100,000 persons, and approximately 148,000 persons are living with PV in the United States. | *The [[prevalence]] of PV is estimated to be 44 to 57 cases per 100,000 persons, and approximately 148,000 persons are living with PV in the United States.<ref name="MehtaWang2013">{{cite journal|last1=Mehta|first1=Jyotsna|last2=Wang|first2=Hongwei|last3=Iqbal|first3=Sheikh Usman|last4=Mesa|first4=Ruben|title=Epidemiology of myeloproliferative neoplasms in the United States|journal=Leukemia & Lymphoma|volume=55|issue=3|year=2013|pages=595–600|issn=1042-8194|doi=10.3109/10428194.2013.813500}}</ref><ref name="SteinOh2015">{{cite journal|last1=Stein|first1=Brady L.|last2=Oh|first2=Stephen T.|last3=Berenzon|first3=Dmitriy|last4=Hobbs|first4=Gabriela S.|last5=Kremyanskaya|first5=Marina|last6=Rampal|first6=Raajit K.|last7=Abboud|first7=Camille N.|last8=Adler|first8=Kenneth|last9=Heaney|first9=Mark L.|last10=Jabbour|first10=Elias J.|last11=Komrokji|first11=Rami S.|last12=Moliterno|first12=Alison R.|last13=Ritchie|first13=Ellen K.|last14=Rice|first14=Lawrence|last15=Mascarenhas|first15=John|last16=Hoffman|first16=Ronald|title=Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery ofJAK2 V617F|journal=Journal of Clinical Oncology|volume=33|issue=33|year=2015|pages=3953–3960|issn=0732-183X|doi=10.1200/JCO.2015.61.6474}}</ref> | ||
===Case-fatality rate/Mortality rate=== | |||
*The 15-year survival of patients with polycythemia vera is 65%.<ref name="pmid15541325">{{cite journal| author=Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M et al.| title=Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. | journal=Am J Med | year= 2004 | volume= 117 | issue= 10 | pages= 755-61 | pmid=15541325 | doi=10.1016/j.amjmed.2004.06.032 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15541325 }} </ref> | |||
*The mortality of polycythemia vera patients compared with the general population is 1.6-fold higher. | |||
===Age=== | ===Age=== | ||
The median age | *The median age at diagnosis is 61 years but has been diagnosed in all age groups. The incidence increases with age.<ref name="pmid26324368">{{cite journal |vauthors=Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK, Abboud CN, Adler K, Heaney ML, Jabbour EJ, Komrokji RS, Moliterno AR, Ritchie EK, Rice L, Mascarenhas J, Hoffman R |title=Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F |journal=J. Clin. Oncol. |volume=33 |issue=33 |pages=3953–60 |date=November 2015 |pmid=26324368 |pmc=4979103 |doi=10.1200/JCO.2015.61.6474 |url=}}</ref> | ||
*Younger patients have comparable rates of [[vascular]] complications compared to older patients. However, [[splanchnic]] vein [[thrombosis]] occur more frequently in younger patients.<ref name="pmid23245211">{{cite journal |vauthors=Stein BL, Saraf S, Sobol U, Halpern A, Shammo J, Rondelli D, Michaelis L, Odenike O, Rademaker A, Zakarija A, McMahon B, Spivak JL, Moliterno AR |title=Age-related differences in disease characteristics and clinical outcomes in polycythemia vera |journal=Leuk. Lymphoma |volume=54 |issue=9 |pages=1989–95 |date=September 2013 |pmid=23245211 |doi=10.3109/10428194.2012.759656 |url=}}</ref> | |||
*Younger patients are more likely to develop unusual complications such as [[mesenteric]] [[venous thrombosis]]. The rate of transformation to [[acute leukemia]] is similar as that of older adults.<ref name="pmid26324368">{{cite journal| author=Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK et al.| title=Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. | journal=J Clin Oncol | year= 2015 | volume= 33 | issue= 33 | pages= 3953-60 | pmid=26324368 | doi=10.1200/JCO.2015.61.6474 | pmc=4979103 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26324368 }} </ref> | |||
===Race=== | |||
* In ashkenazi jews, there is a high incidence of polycythemia vera.<ref name="pmid27884974">{{cite journal| author=Vannucchi AM| title=From leeches to personalized medicine: evolving concepts in the management of polycythemia vera. | journal=Haematologica | year= 2017 | volume= 102 | issue= 1 | pages= 18-29 | pmid=27884974 | doi=10.3324/haematol.2015.129155 | pmc=5210229 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27884974 }} </ref> | |||
===Gender=== | ===Gender=== | ||
Males are more commonly affected with polycythemia vera than females | *Males are more commonly affected with polycythemia vera than females. The male to female ratio is approximately 1.2 to 1.<ref name="pmid26324368">{{cite journal |vauthors=Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK, Abboud CN, Adler K, Heaney ML, Jabbour EJ, Komrokji RS, Moliterno AR, Ritchie EK, Rice L, Mascarenhas J, Hoffman R |title=Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F |journal=J. Clin. Oncol. |volume=33 |issue=33 |pages=3953–60 |date=November 2015 |pmid=26324368 |pmc=4979103 |doi=10.1200/JCO.2015.61.6474 |url=}}</ref> | ||
==References== | ==References== | ||
| Line 27: | Line 33: | ||
{{Hematology}} | {{Hematology}} | ||
{{Hematological malignancy histology}} | {{Hematological malignancy histology}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
Latest revision as of 02:58, 14 September 2019
|
Polycythemia vera Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Polycythemia vera epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Polycythemia vera epidemiology and demographics |
|
Risk calculators and risk factors for Polycythemia vera epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ifeoma Odukwe, M.D. [2] Mohamad Alkateb, MBBCh [3] Shyam Patel [4]
Overview
The incidence of polycythemia vera is approximately 1.9 per 100,000 individuals per year in the US. The prevalence of polycythemia vera is 48 to 57 cases per 100,000 individuals in the United States. Males are more commonly affected than females.
Epidemiology and Demographics
Incidence
- The incidence of polycythemia vera is about 1.9 per 100,000 individuals per year in the US. The incidence rate for men is 2.8 per 100,000 person-years, and is 1.3 per 100,000 person years for women.[1]
Prevalence
- The prevalence of PV is estimated to be 44 to 57 cases per 100,000 persons, and approximately 148,000 persons are living with PV in the United States.[2][3]
Case-fatality rate/Mortality rate
- The 15-year survival of patients with polycythemia vera is 65%.[4]
- The mortality of polycythemia vera patients compared with the general population is 1.6-fold higher.
Age
- The median age at diagnosis is 61 years but has been diagnosed in all age groups. The incidence increases with age.[5]
- Younger patients have comparable rates of vascular complications compared to older patients. However, splanchnic vein thrombosis occur more frequently in younger patients.[6]
- Younger patients are more likely to develop unusual complications such as mesenteric venous thrombosis. The rate of transformation to acute leukemia is similar as that of older adults.[5]
Race
- In ashkenazi jews, there is a high incidence of polycythemia vera.[7]
Gender
- Males are more commonly affected with polycythemia vera than females. The male to female ratio is approximately 1.2 to 1.[5]
References
- ↑ Anía BJ, Suman VJ, Sobell JL, Codd MB, Silverstein MN, Melton LJ (1994). "Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989". Am J Hematol. 47 (2): 89–93. PMID 8092146.
- ↑ Mehta, Jyotsna; Wang, Hongwei; Iqbal, Sheikh Usman; Mesa, Ruben (2013). "Epidemiology of myeloproliferative neoplasms in the United States". Leukemia & Lymphoma. 55 (3): 595–600. doi:10.3109/10428194.2013.813500. ISSN 1042-8194.
- ↑ Stein, Brady L.; Oh, Stephen T.; Berenzon, Dmitriy; Hobbs, Gabriela S.; Kremyanskaya, Marina; Rampal, Raajit K.; Abboud, Camille N.; Adler, Kenneth; Heaney, Mark L.; Jabbour, Elias J.; Komrokji, Rami S.; Moliterno, Alison R.; Ritchie, Ellen K.; Rice, Lawrence; Mascarenhas, John; Hoffman, Ronald (2015). "Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery ofJAK2 V617F". Journal of Clinical Oncology. 33 (33): 3953–3960. doi:10.1200/JCO.2015.61.6474. ISSN 0732-183X.
- ↑ Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M; et al. (2004). "Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia". Am J Med. 117 (10): 755–61. doi:10.1016/j.amjmed.2004.06.032. PMID 15541325.
- ↑ 5.0 5.1 5.2 Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK, Abboud CN, Adler K, Heaney ML, Jabbour EJ, Komrokji RS, Moliterno AR, Ritchie EK, Rice L, Mascarenhas J, Hoffman R (November 2015). "Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F". J. Clin. Oncol. 33 (33): 3953–60. doi:10.1200/JCO.2015.61.6474. PMC 4979103. PMID 26324368.
- ↑ Stein BL, Saraf S, Sobol U, Halpern A, Shammo J, Rondelli D, Michaelis L, Odenike O, Rademaker A, Zakarija A, McMahon B, Spivak JL, Moliterno AR (September 2013). "Age-related differences in disease characteristics and clinical outcomes in polycythemia vera". Leuk. Lymphoma. 54 (9): 1989–95. doi:10.3109/10428194.2012.759656. PMID 23245211.
- ↑ Vannucchi AM (2017). "From leeches to personalized medicine: evolving concepts in the management of polycythemia vera". Haematologica. 102 (1): 18–29. doi:10.3324/haematol.2015.129155. PMC 5210229. PMID 27884974.